moneyheap
VRTX · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Vertex Pharmaceuticals Inc (VRTX) stock moving?
Vertex reported Q3 2026 revenue of $3.44B, up 12%, driven by cystic fibrosis therapies and newer launches such as CASGEVY, JOURNAVX and PALSONIFY, and raised full-year revenue guidance to $13.15B-$13.25B. GAAP net income fell to $654M from $1.1B, mainly due to about $500M of Crinetics acquisition and compensation costs and higher R&D, acquired IPR&D and SG&A spending. Following the results, a broad wave of analyst price-target increases followed from Goldman Sachs ($725), Scotiabank ($660), Wells Fargo ($650), UBS ($640), Daiwa ($640), Bernstein ($620), Barclays ($626), RBC ($600) and TD Cowen ($575), with Morgan Stanley trimming to $660, and Needham reaffirming Buy. The main near-term catalyst is the povetacicept IgAN PDUFA date on November 30, which would establish a fifth commercial franchise, while Evotec's manufacturing pause at its J.POD Redmond facility is a supply-side risk to watch. Market data shows the stock rallied from about $517 on Oct 26 to a $558.88 close on Oct 30 and a $568.67 intraday high on Nov 2 on heavy volume of about 3.2M shares. Since then it has settled near $548, with volume normalizing to about 1.2M shares, and most current price targets sit above the last price. The Form 144 filing is small and not a meaningful signal on its own.
News behind the analysis
- Vertex Reports Third Quarter 2026 Financial ResultsQ3 total revenue rose 12% to $3.44B, and full-year 2026 revenue guidance was raised to $13.15B-$13.25B. The company also closed the Crinetics acquisition and expects a povetacicept PDUFA date on November 30.
- Vertex Pharmaceuticals Recognized in BioSpace 2027 Best Places to Work ListVertex was named a winner in the BioSpace 2027 Best Places to Work list for life sciences. This is a reputational item with no direct financial impact.
- Daiwa Securities Adjusts Price Target on Vertex PharmaceuticalsDaiwa raised its price target on Vertex from $556 to $640.
- Evotec Announces Manufacturing Pause for Vertex's PovetaciceptEvotec announced a temporary manufacturing pause for povetacicept at its J.POD Redmond facility to install a third production train. This is a supply-side item to monitor ahead of the PDUFA date.
- Vertex Pharmaceuticals Executive Files Form 144 for Share SaleExecutive Reshma Kewalramani filed a Form 144 to sell 11,900 shares of common stock. The size is small relative to daily volume.
- Needham Maintains Buy Rating and Raises Price Target for Vertex PharmaceuticalsNeedham reaffirmed its Buy rating on Vertex and raised its price target.
- Bernstein Increases Price Target on Vertex PharmaceuticalsBernstein raised its price target on Vertex to $620 from $608.
- Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $626Barclays kept its Overweight rating and raised its price target on Vertex to $626 from $617.
- Goldman Sachs Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $725Goldman Sachs kept its Buy rating and raised its price target on Vertex to $725, the highest target among the recent updates.
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals is a Boston-based biotech company. It dominates the treatment of cystic fibrosis, with medicines that target the underlying cause of the disease, and is now branching out into sickle cell gene editing, non-opioid pain relief, rare hormone (endocrine) disorders and kidney disease. Its 2026 revenue guidance is roughly $13.2 billion.
How it makes money
Most of its revenue, roughly 95% or more, comes from cystic fibrosis drugs such as TRIKAFTA/KAFTRIO and ALYFTREK. Newer products are a small but growing share, guided at about $500 million or more in 2026. These include CASGEVY, a gene-editing therapy for sickle cell disease and beta thalassemia; JOURNAVX, a non-opioid pain medicine for short-term (acute) pain; and PALSONIFY, a rare endocrine drug it gained by buying Crinetics in 2026 for about $10 billion. The company also has a kidney-disease drug, povetacicept for IgA nephropathy, awaiting an FDA decision due by November 30, 2026.
What usually moves VRTX
- Cystic fibrosis franchise sales and pricing
- Launch uptake of CASGEVY and JOURNAVX
- FDA decisions and clinical trial results (e.g., povetacicept)
- Acquisitions and diversification beyond cystic fibrosis
- Drug pricing policy and reimbursement